Dealing with diversity in computational cancer modeling

Cancer Informatics

Volumn 12, Issue , 2013, Pages 115-124

  Johnson, David ^a   McKeever, Steve ^b   Stamatakos, Georgios ^c   Dionysiou, Dimitra ^c   Graf, Norbert ^d   Sakkalis, Vangelis ^e   Marias, Konstantinos ^e   Wang, Zhihui ^f   Deisboeck, Thomas S ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS   (Greece)

^d SAARLAND UNIVERSITY   (Germany)

^e INSTITUTE OF COMPUTER SCIENCE   (Greece)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

In silico oncology; Model interoperability; Multi scale computational tumor modeling; XML markup languages

Indexed keywords

BRAIN TUMOR; CANCER MODEL; CANCER RESEARCH; CELLML; COMPUTER MODEL; COMPUTER SIMULATION; DIFFUSION WEIGHTED IMAGING; INFORMATION PROCESSING; INSILICOML; LANGUAGE PROCESSING; MARKUP LANGUAGE; MATHEMATICAL COMPUTING; MATHML; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; SBML; SYSTEMS BIOLOGY; VALIDATION PROCESS; VIRTUAL REALITY; XML;

EID: 84877759913     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S11583     Document Type: Note

References (69)

1. Anderson AR, Quaranta V. Integrative mathematical oncology. Nat Rev Cancer. 2008;8(3):227-34.
2. Deisboeck TS, Zhang L, Yoon J, Costa J. In silico cancer modeling: is it ready for prime time? Nat Clin Pract Oncol. 2009;6(1):34-42.
3. Ventura AC, Jackson TL, Merajver SD. On the role of cell signaling models in cancer research. Cancer Res. 2009;69(2):400-2.
4. Enderling H, Chaplain MA, Anderson AR, Vaidya JS. A mathematical model of breast cancer development, local treatment and recurrence. J Theor Biol. 2007;246(2):245-59.
5. Powathil G, Kohandel M, Sivaloganathan S, Oza A, Milosevic M. Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy. Phys Med Biol. 2007;52(11):3291-306.
6. Marias K, Sakkalis V, Roniotis A, et al. Clinically oriented translational cancer multilevel modeling: The ContraCancrum project. In: Dössel O, Schlegel WC, editors. IFMBE Proceedings 25(4), World Congress on Medical Physics and Biomedical Engineering, Sep 7-12, 2009, Munich, Germany. Berlin, Germany: Springer-Verlag; 2010:2124-7.
7. Dionysiou D, Stamatakos G, Gintides D, Uzunoglu N, Kyriaki K. Critical parameters determining standard radiotherapy treatment outcome for glioblastoma multiforme: a computer simulation. Open Biomed Eng J. 2008;2:43-51.
8. Stamatakos G, Antipas V, Uzunoglu N. A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide. IEEE Trans Biomed Eng. 2006;53(8):1467-77.
9. Rockne R, Alvord EC, Szeto M, Gu S, Chakraborty G, Swanson KR. Modeling diffusely invading brain tumors an individualized approach to quantifying glioma evolution and response to therapy. In: Selected Topics in Cancer Modeling. Boston, MA: Birkhäuser; 2008:1-15.
10. Sottoriva A, Verhoe JJ, Borovski T, et al. Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res. 2010;70(1):46-56.
11. Frieboes HB, Zheng X, Sun CH, Tromberg B, Gatenby R, Cristini V. An integrated computational/experimental model of tumor invasion. Cancer Res. 2006;66(3):1597-604.
12. Castorina P, Carcò D, Guiot C, Deisboeck TS. Tumor growth instability and its implications for chemotherapy. Cancer Res. 2009;69:8507-15.
13. Sakkalis V, Roniotis A, Farmaki C, Karatzanis I, Marias K. Evaluation framework for the multilevel macroscopic models of solid tumor growth in the glioma case. Conf Proc IEEE Eng Med Biol Soc. 2010;2010: 6809-12.
14. Roniotis A, Marias K, Sakkalis V, Zervakis M. Diffusive modeling of glioma evolution: a review. J Biomed Sci Eng. 2010;3(5):501-8.
15. Dionysiou D, Stamatakos G, Uzunoglu N, Nikita KS, Marioli A. A four dimensional simulation model of tumour response to radiotherapy in vivo: parametric validation considering radiosensitivity, genetic profile and fractionation. J Theor Biol. 2004;230(1):1-20.
16. Dionysiou D, Stamatakos G. Applying a 4D multiscale in vivo tumor growth model to the exploration of radiotherapy scheduling: the effects of weekend treatment gaps and p53 gene status on the response of fast growing solid tumors. Cancer Inform. 2007;2:113-21.
17. Ubezio P, Cameron D. Cell killing and resistance in pre-operative breast cancer chemotherapy. BMC Cancer. 2008;8:201.
18. Titz B, Jeraj R. An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response. Phys Med Biol. 2008;53(17):4471-88.
19. Anderson AR, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell. 2006;127(5):905-15.
20. Duechting W, Ulmer W, Lehrig R, Ginsberg T, Dedeleit E. Computer simulation and modelling of tumor spheroid growth and their relevance for optimization of fractionated radiotherapy. Strahlenther Onkol. 1992;168(6):354-60.
21. Norris V, Cabin A, Zermiline A. Hypercomplexity. Acta Biotheor. 2005; 53(4):313-30.
22. Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol Syst Biol. 2009;5:249.
23. Lowengrub JS, Frieboes HB, Jin F, et al. Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity. 2010; 23(1):R1-9.
24. Sanga S, Frieboes HB, Zheng X, Gatenby R, Bearer EL, Cristini V. Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth. Neuroimage. 2007;37(Suppl 1):S120-34.
25. Wang Z, Deisboeck TS. Computational modeling of brain tumors: discrete, continuum or hybrid? Sci Model Simul. 2008;15:381-93.
26. Noble D. The rise of computational biology. Nat Rev Mol Cell Biol. 2002;3(6):459-63.
27. Wang Z, Zhang L, Sagotsky J, Deisboeck TS. Simulating non-small cell lung cancer with a multiscale agent-based model. Theor Biol Med Model. 2007;4:50.
28. Wang Z, Birch CM, Deisboeck TS. Cross-scale sensitivity analysis of a non-small cell lung cancer model: Linking molecular signaling properties to cellular behavior. Biosystems. 2008;92(3):249-58.
29. Wang Z, Birch CM, Sagotsky J, Deisboeck TS. Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model. Bioinformatics. 2009;25(18):2389-96.
30. Wang Z, Bordas V, Sagotsky J, Deisboeck TS. Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model. Math Med Biol. 2012;1:95-108.
31. Gerlee P, Anderson A. An evolutionary hybrid cellular automaton model of solid tumour growth. J Theor Biol. 2007;246(4):583-603.
32. Gerlee P, Anderson A. A hybrid cellular automaton model of clonal evolution in cancer: the emergence of the glycolytic phenotype. J Theor Biol. 2008;250(4):705-22.
33. Gerlee P, Anderson A. Evolution of cell motility in an individual-based model of tumour growth. J Theor Biol. 2009;259(1):67-83.
34. Ramis-Conde I, Drasdo D, Anderson AR, Chaplain MA. Modeling the influence of the E-Cadherin-β-Catenin pathway in cancer cell invasion: a multiscale approach. Biophys J. 2008;95(1):155-65.
35. Ramis-Conde I, Chaplain MA, Anderson AR, Drasdo D. Multi-scale modelling of cancer cell intravasation: the role of cadherins in metastasis. Phys Biol. 2009;6(1):016008.
36. Stamatakos GS, Dionysiou D, Graf N, et al. The "Oncosimulator": a multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silico oncology. Conf Proc IEEE Eng Med Biol Soc. 2007;2007: 6629-32.
37. Graf N, Hoppe A, Georgiadi E, et al. 'In silico' oncology for clinical decision making in the context of nephroblastoma. Klin Padiatr. 2009; 221(3):141-9.
38. Clapworthy GJ, Kohl P, Gregerson H, et al. Digital human modelling: a global vision and a European perspective. In: Digital Human Modeling, Lecture Notes in Computer Science. 2007;4561:549-58.
39. Martin L, Anguita A, Graf N, et al. ACGT: advancing clinico-genomic trials on cancer-four years of experience. Stud Health Technol Inform. 2011;169: 734-8.
40. Deisboeck TS, Zhang L, Martin S. Advancing cancer systems biology: introducing the Center for the Development of a Virtual Tumor, CViT. Cancer Inform. 2007;5:1-8.
41. Sakkalis V, Marias K, Stamatakos, G, et al. The TUMOR project: integrating cancer model repositories for supporting predictive oncology. In: Abstract Booklet for VPH2012 Integrative Approaches to Computational Biomedicine. September 18-20, 2012; London, UK.
42. Louis D, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
43. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
44. Warmuth-Metz M. Neuroradiologie bei gliomen und metastasen. Der Onkologe. 2011;17(1):18-30.
45. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59(6):947-9.
46. Rees J. Glioma therapy. ACNR. 2002;2(2):11.
47. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96.
48. Krex D, Klink B, Hartmann C, von Deimling A, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(Pt 10):2596-606.
49. Hegi ME, DiserensAC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
50. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-72.
51. Zepp J, Graf N, Skounakis E, et al. Tumor segmentation: The impact of standardized signal intensity histograms in glioblastoma. In: Proceedings of the 4th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation. Athens, Greece; Sep 8-9, 2010:98-9.
52. Bray T, Paoli J, Sperberg-McQueen C, Maler E, Yergeau F, editors. Extensible Markup Language (XML) 1.0, 5th ed. W3C Recommendation 26 Nov 2008. http://www.w3.org/TR/2008/REC-xml-20081126/. Accessed April 18, 2013.
53. Wiggins R. XML: An interview with Peter Flynn. IEEE Comput. 2000;33(4):113-6.
54. Hucka M, Finney A, Bornstein BJ, et al. Evolving a lingua franca and associated software infrastructure for computational systems biology: the Systems Biology Markup Language (SBML) project. IET Syst Biol. 2004;1(1):41-53.
55. Hucka M, Bergmann F, Hoops S, Keating SM, Sahle S, Wilkinson DJ. The Systems Biology Markup Language (SBML): language specification for level 3 version 1 Core (release 1 candidate). Nature Precedings. 2010. http://dx.doi.org/10.1038/npre.2010.4123.1. Accessed Jan 8, 2013.
56. Carlisle D, Ion P, Miner R, et al. Mathematical Markup Language (MathML) version 3.0. W3C Recommendation 21. 2010.
57. Cuellar AA, Lloyd CM, Nielsen PF, Bullivant DP, Nickerson DP, Hunter PJ. An overview of CellML 1.1, a biological model description language. SIMUL. 2003;79(12):740-7.
58. Lloyd CM, Halstead MD, Nielsen PF. CellML: its future, present and past. Prog Biophys Mol Biol. 2004;85(2-3):433-50.
59. Christie GR, Nielsen PM, Blackett SA, Bradley CP, Hunter PJ. FieldML: concepts and implementation. Philos Transact A Math Phys Eng Sci. 2009; 367(1895):1869-84.
60. Asai Y, Suzuki Y, Kido Y, et al. Specifications of insilicoML 1.0: a multilevel biophysical model description language. J Physiol Sci. 2008;58(7):447-58.
61. Suzuki Y, Asai Y, Kawazu T, et al. A platform for in silico modeling of physiological systems II. CellML compatibility and other extended capabilities. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:573-6.
62. Suzuki Y, Asai Y, Oka H, et al. A platform for in silico modeling of physiological systems III. Conf Proc IEEE Eng Med Biol Soc. 2009;2009: 2803-6.
63. Johnson D, McKeever S. The case for using markup for biomechanical modelling. In: Proc Internat Soc Biomech XXIII World Congr. 2011.
64. Johnson D, Cooper J, McKeever S. Markup languages for in silico oncology, In: Proceedings of the 4th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation. Athens, Greece, Sep 8-9, 2010:108-10.
65. Johnson D, Cooper J, McKeever S. TumorML: Concept and requirements of an in silico cancer modelling markup language. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:441-4.
66. Anjomshoaa A, Brisard F, Drescher M, et al. Job Submission Description Language (JSDL) Specification, Version 1.0. Technical Report. Global Grid Forum. 2005.
67. Johnson D, Connor AJ, McKeever S. Modular markup for simulating vascular tumour growth. In: Proceedings of the 4th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation. Athens, Greece; Sep 8-9, 2010:53-6.
68. Köhn D, Novère N. SED-ML-an XML format for the implementation of the MIASE guidelines. In: Computational Methods in Systems Biology, Lecture Notes in Computer Science. 2008;5307:176-90.
69. Calinescu R, Harris S, Gibbons J, Davies J. Cross-trial query system for cancer clinical trials, In: Sobh T, editor. Innovations and Advanced Techniques in Computer and Information Sciences and Engineering. Dordrecht, The Netherlands: Springer Netherlands; 2007:385-90.